Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 21 to 30 of 365 total matches.
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
) .................................. p 35
The Medical Letter ® Vol. 66 (1697) March 4, 2024
34
Systemic estrogen can also help ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
%)
The Medical Letter ® Vol. 66 (1697) March 4, 2024
39
1. Tenapanor (Ibsrela) for irritable bowel syndrome ...
The FDA has approved the sodium/hydrogen
exchanger 3 (NHE3) inhibitor tenapanor (Xphozah –
Ardelyx) to reduce serum phosphorus in adults with
chronic kidney disease (CKD) on dialysis as add-on
therapy when phosphate binders are ineffective or
as monotherapy when phosphate binders cannot be
tolerated. Tenapanor is the first NHE3 inhibitor to be
approved in the US for hyperphosphatemia. It was
previously approved as Ibsrela to treat irritable bowel
syndrome with constipation (IBS-C).
Med Lett Drugs Ther. 2024 Mar 4;66(1697):38-9 doi:10.58347/tml.2024.1697b | Show Introduction Hide Introduction
In Brief: Severe Hypocalcemia with Denosumab (Prolia) in Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
Letter ® Vol. 66 (1697) March 4, 2024 vitamin D calcium supplements postmenopausal osteoporosis ...
The FDA is requiring a boxed warning in the label
of denosumab (Prolia – Amgen), a monoclonal
antibody that inhibits osteoclasts, about an
increased risk of severe hypocalcemia in patients
with advanced chronic kidney disease (CKD;
eGFR <30 mL/min/1.73 m2), particularly those on
dialysis. FDA-approved indications for Prolia are
listed in Table 1.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):40 doi:10.58347/tml.2024.1697c | Show Introduction Hide Introduction
Capivasertib (Truqap) for Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
approved for use in those with AKT
pathway-altered tumors.
e33
The Medical Letter ® Vol. 66 Published ...
The oral kinase inhibitor capivasertib (Truqap –
AstraZeneca), a first-in-class AKT inhibitor, has
been approved by the FDA for use in combination
with the selective estrogen receptor degrader (SERD)
fulvestrant (Faslodex, and generics) for treatment of
hormone receptor (HR)-positive, human epidermal
growth factor receptor 2 (HER2)-negative, locally
advanced or metastatic breast cancer in adults with
one or more PIK3CA/AKT1/PTEN-alterations who had
disease progression on at least one endocrine-based
regimen for metastatic disease or recurrence on or
within 12 months of completing...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e32-3 doi:10.58347/tml.2024.1696e | Show Introduction Hide Introduction
Repotrectinib (Augtyro) for Non-Small Cell Lung Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
(steady state)
e37
The Medical Letter ® Vol. 66 Published online February 19, 2024
34.1 months. Among ...
The FDA has approved the oral tyrosine kinase
inhibitor repotrectinib (Augtyro – BMS) for treatment
of locally advanced or metastatic ROS1-positive
non-small cell lung cancer (NSCLC) in adults.
Repotrectinib is the third oral tyrosine kinase inhibitor
to be approved for this indication in the US; crizotinib
(Xalkori) and entrectinib (Rozlytrek) were approved
earlier.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e36-7 doi:10.58347/tml.2024.1696g | Show Introduction Hide Introduction
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
colorectal cancer, regardless of biomarker status.
The Medical Letter ® Vol. 66 Published online February 19 ...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):e34-5 doi:10.58347/tml.2024.1696f | Show Introduction Hide Introduction
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
. A coprimary endpoint.
The Medical Letter ® Vol. 66 (1696) February 19, 2024
Daprodustat was noninferior ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction
Cantharidin Topical Solution (Ycanth) for Molluscum Contagiosum
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
in exposure of the fetus or the breastfed
infant to the drug.
The Medical Letter ® Vol. 66 (1696) February ...
The FDA has approved cantharidin 0.7% solution
(Ycanth – Verrica) for topical treatment of molluscum
contagiosum in patients ≥2 years old. Ycanth
was the first drug to be approved in the US for this
indication. A 10.3% gel formulation of berdazimer
(Zelsuvmi), a nitric oxide-releasing agent, has
also been approved by the FDA for treatment of
molluscum contagiosum (in patients ≥1 year old); it
will be reviewed in a future issue.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):27-9 doi:10.58347/tml.2024.1696b | Show Introduction Hide Introduction
Rozanolixizumab (Rystiggo) for Myasthenia Gravis
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
corticosteroid,
or other immunosuppressive drug). About 90%
The Medical Letter ® Vol. 66 (1696) February 19 ...
Rozanolixizumab-noli (Rystiggo – UCB), a neonatal
Fc receptor (FcRn) blocker, has been approved by the
FDA for treatment of generalized myasthenia gravis in
adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
It is the first drug to be approved for treatment of
generalized myasthenia gravis in patients with anti-MuSK antibodies. Four other biologic drugs – the
FcRn blocker efgartigimod alfa (Vyvgart; Vyvgart
Hytrulo) and the complement inhibitors eculizumab
(Soliris), ravulizumab (Ultomiris), and zilucoplan
(Zilbrysq) – are...
Med Lett Drugs Ther. 2024 Feb 19;66(1696):29-31 doi:10.58347/tml.2024.1696c | Show Introduction Hide Introduction
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
® Vol. 66 (1696) February 19, 2024
The
Medical
Letter
. For elevated INR and major bleeding, both ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction